An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
This study is an open-label, multicenter, extension study for subjects who completed
 NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks
 (up to +7days) before entry into Study C114
Key Eligibility Criteria:

 -  Must have completed NeurogesX Study C111 and received treatment with NGX-4010
 (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114.

 -  Demonstrated adherence to protocol requirements during Study C111, and willing and
 able to comply with protocol requirements for the duration of the study participation.

 -  Must not have had any serious adverse experience since enrollment in Study C111,
 whether or not considered to be study drug-related.

 -  Must have intact skin at the treatment area.

 -  Must be prepared to remain on the same pain medications at the same doses as before
 the study for the entire duration of the study (36 weeks).

 -  Must not use topical pain medications on painful areas.

 -  Must be at least 18 years old, not pregnant, and able to take care of self
 independently, with only occasional assistance if needed.

 -  No history or current problem with substance abuse.